<DOC>
	<DOCNO>NCT01329250</DOCNO>
	<brief_summary>The main objective prospective clinical trial compare pharmacokinetics safety tolerability standard dose ( 400 mg ) escalate dose ( 600 mg ; 800 mg ) moxifloxacin ( MFX ) . This clinical trial provide important safety information MFX high dosage TB patient .</brief_summary>
	<brief_title>Pharmacokinetics Safety Moxifloxacin</brief_title>
	<detailed_description>Moxifloxacin ( MFX ) fluoroquinolone high vitro vivo bactericidal activity Mycobacterium tuberculosis . A daily dose 600-800 mg MFX consider optimal kill involved mycobacteria suppression drug resistance , high currently use dose 400 mg daily . In general , safety data support switch suggest high dose limit . For purpose , twenty tuberculosis patient start standard dose MFX 400 mg daily . After 8 day dose increased 600 mg daily 15th day treatment , dose MFX escalate 800 mg . In patient treat rifampicin ( RIF ) past three week prior start MFX treatment additional washout period 3 week reduce rifampicin induce enzymatic activity precede dose escalation .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Patients TB , Mycobacterium tuberculosis ( M. africanum ) culture Starting treatment MFX dose 400 mg part TB treatment Contraindication MFX Baseline QTcinterval &gt; 450 msec History resuscitation History ventricular tachycardia ( include Torsades de Pointes ) Family history sudden cardiac death Torsades de Pointes Additional risk factor Torsades de Pointes ( include know heart failure , Left ventricular hypertrophy ) Use concomitant treatment QT/QTc prolonging drug ( include antidysrhythmics class IA III , antipsychotic , tricyclic antidepressant antihistaminic drug terfenadine ) Abnormal electrolytes ( K , Mg , Na , Ca ) Abnormal cardiac repolarisation screening/baseline ECG History adverse event fluoroquinolones HIV coinfection RIF treatment last 3 week start study . After washout period 3 week patient include .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
</DOC>